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Abstract. The Web is a potentially huge source of medical drug leads. But 
despite the significant amount of multi-dimensional information about drugs, 
currently commercial search engines accept only linear keyword strings as 
inputs. This work uses linearized fragments of molecular structures as 
knowledge representation units to serve as inputs to search engines. It is shown 
that quite arbitrary fragments are surprisingly free of ambiguity, obtaining 
relatively small result sets, which are both manageable and rich in novel 
potential drug leads.   
Keywords. Linearized chemical structures, lead, search, multi-dimensional, 
knowledge representation. 
1 Introduction 
Development of new medical drugs is an extremely long and expensive process (see 
e.g. [11]). It commonly starts from molecule components with potential desirable 
activity – called leads (e.g. [3]) – that are gradually improved by adding or modifying 
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groups of atoms that are part of the leads, to increase activity and decrease undesirable 
side-effects. In pharmaceutical terms, the active groups of atoms that build together 
the leads are often referred as ligands or just fragments. 
Web search is a promising source of leads to new drugs. But, much of the 
information available about potential drug molecules is either two-dimensional – e.g. 
planar structural formulas as seen in the next sections – or three-dimensional 
conformation models. This is an obstacle to search by the generic search engines that 
are currently limited to one-dimensional keyword strings. 
The solution proposed along this work [2] is to characterize drugs by linearized 
structures that can be sliced into fragments. These fragments can be directly used as 
search inputs and be stored in suitable ontologies. 
The remaining of the paper deals with medical drug knowledge representation 
issues (section 2), describes specialized medical drug ontologies (section 3), presents 
preliminary search results (section 4), and concludes with a discussion (section 5). 
2 Drug Knowledge Representation 
Generic search engines are powerful and widely available. They easily deal with 
textual information. 
Medical drugs are based on an active chemical substance, represented by a 
molecule. Formally, molecules essentially are graphs with edges connecting discrete 
entities standing for atoms or groups of atoms. Knowledge about a substance contains 
several information types, of which not all of them can directly serve as input to 
search engines (see e.g. Konyk at al. [4], and Searls [7]). 
Two-Dimensional (2-D) and three-Dimensional (3-D) kinds of information about 
molecules are amenable to linearization, thus can be useful as search inputs. We 
mention two of the most common systems of molecular naming that translate 
structural graph information to compact linear strings. 
2.1 SMILES  
SMILES – an acronym of "Simplified Molecular Input Line Entry" – was proposed by 
Weininger et al. (see [9], [10]). OpenSMILES [6] is a more recent open standard 
variant. SMILES unambiguously describes 2-D or 3-D molecular structures using 
ASCII strings1. The latter can be imported by molecular editor tools to convert them 
back into 2-D or 3-D molecular structures. Thus one manipulates multi-dimensional 
and linearized structures in practice. 
The SMILES string is obtained by a depth-first tree traversal of the molecule graph. 
Hydrogen atoms implied by the graph skeleton are trimmed. Cycles are broken turning 
a graph into a spanning tree (numeric suffixes indicate the connected nodes of broken 
cycles). Parentheses indicate branching points of the tree.  
                                                          
1
 Please refer to the literature about SMILES’ requirements for unique specification. 
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Nelarabine – a chemotherapy drug used to treat leukemia – provides a first example 
of a linearized structure in this paper. Its molecular formula is C11H15N5O5. Fig. 1 
displays a SMILES string for this substance. Fig. 2 shows its 2-D structure. 
 
 
 
 
Fig. 1. Nelarabine SMILES String – A linearized string representation of Nelarabine whose 
two-dimensional structure is seen in Fig. 2. Here one can count e.g. 11 carbon atoms C and 5 
nitrogen N and 5 oxygen O atoms. Hydrogen atoms H are implicit. 
 
 
 
Fig. 2. Nelarabine 2-D Structure – This formula displays one hexagonal and two pentagonal 
rings. Also seen atoms and groups (say NH2=Amino), linked by chemical bonds. In contrast to 
Fig. 1, some hydrogen atoms H are here explicit, while carbon atoms C are implied by 
unnamed vertices of the polygons. 
 
Midazolam – a hypnotic-sedative drug – with molecular formula C18H13ClFN3 is our 
second example of a linearized structure. Fig. 3 displays its SMILES string. 
Midazolam’s 2-D structure is shown in Fig. 4. 
 
 
 
Fig. 3. Midazolam SMILES String –  Again one can count atom types, except hydrogen H, and 
compare with its molecular formula. It has one chlorine Cl and one fluorine F atom. 
 
 
 
 
 
 
Fig. 4. Midazolam 2-D Structure – It shows a pentagonal, two hexagonal and a heptagonal 
ring. Also explicit some of its atoms (N=Nitrogen, F=Fluor, Cl=Chlorine). 
 
2.2 InChi 
 
InChI – an "International Chemical Identifier" – was proposed by the International 
Union of Pure and Applied Chemistry (IUPAC) in 2006 [5]. It has the same purpose 
as SMILES. 
COC1=NC(N)=NC2=C1N=CN2C1OC(CO)C(O)C1O 
CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F 
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Each molecular structure has a unique InChI string. The InChI format, algorithms 
and software are freely available. Search speed is increased by a hashed InChI – the 
InChIKey – having a fixed 25 character length, a human unreadable form of the InChI 
descriptor.  
InChI describes chemicals in a set of information layers (atoms, connectivity, 
isotopes, stereo, etc.). A particular InChI descriptor may contain only some of these 
layers.  
SMILES may be less expressive in terms of kinds of information, but it is certainly 
more human readable than InChI. Therefore we have chosen SMILES for this work.  
3 Medical Drug Ontologies 
Linearized fragments – i.e. whole groups within molecules – are meant to be used as 
inputs for Lead search. We first concisely review conventional medical drug 
ontologies, then describe specialized ontologies which store linearized fragments. 
3.1 Conventional Medical Drug Ontologies 
Medical drug and chemical ontologies found in the literature contain detailed and 
comprehensive descriptions of concepts in the field (e.g. [1], [8]).  
The chemical information ontology [1] formulated in OWL (the Web Ontology 
description Language), precisely defines each of the concepts mentioned in the 
previous section (molecular formula, structural formula, SMILES, InChi, InChiKey, 
etc.) among many others.  
The Translational Medicine Ontology (TMO) [8] was developed by the W3C 
(World Wide Web Consortium), within the semantic web for health care. TMO is a 
patient-centric ontology to integrate data across aspects of drug discovery and clinical 
practice. TMO is so high-level that it is not really relevant to drug discovery efforts. 
3.2 Specialized Ontologies for Medical Drug Search  
This work proposed specialized "drug-lead" ontologies as repositories of the 
knowledge acquired about active components in medical drugs. 
The drug-lead ontologies are not intended to be comprehensive, but rather concise, 
to facilitate direct and efficient search. Their simple structure has a certain class of 
drugs – e.g. chemotherapy drugs – as a root. A particular drug instance – say 
Nelarabine – displays its important components, either by conventional names or 
linearized structures.  
If the important components do not cover the whole molecule, one adds a place-
holder termed "skeleton" to notify that the molecular structure contains more 
components than the explicitly mentioned ones. In other words, skeleton is part of the 
semantically neutral specification of the structure. This is schematically seen in Fig. 5. 
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Fig. 5. Nelarabine Drug-Lead Ontology – A schematic graph contains the root drug class 
(Chemoterapy), the Nelarabine instance and its named components – a linearized SMILES sub-
string, a conventional Component-A, and an unspecified skeleton. 
Using linearized fragments, say "(N)=NC2=C1N=CN2C" as input to a generic search 
engine, one actually gets among search results potential leads for the given drug class. – in this 
case Nelarabine among other chemotherapy drugs – whose structure contains the component. 
4 Preliminary Results 
4.1 Experimental Technique  
In order to obtain preliminary evaluations for the potential of Web search techniques 
for drug leads, a set of representative structures of diverse drug classes was chosen. 
From each representative a random selection of fragments with increasing size was 
taken and search performed. A few kinds of results were examined, in particular the 
presence of leads of potential interest (see ref. [2]) and the size trend of the result sets. 
The latter are shown next. 
4.2 Search Result Set Sizes  
In the next figures one sees search result set sizes for Nelarabine and Midazolam. 
They are shown as numerical tables and in graphical form. 
 
 
 
Fig. 6. Nelarabine Result Sets for Increasing Fragment Size – Fragment size increases from 2 
symbols – either atoms or other SMILES symbols (equality or parenthesis) – up to 18 symbols. 
Search result set sizes are also shown in logarithmic scale. 
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Fig. 7. Nelarabine Result Sets for Increasing Fragment Size – Graph showing fragment size 
increasing from 2 to 18 symbols. Search result set sizes are shown in logarithmic scale. Square 
(blue) dots are individual results. Continuous (black) straight line is a fitted interpolation. 
 
Fig. 8. Midazolam Result Sets for Increasing Fragment Size – Fragment size increases from 2 
symbols – either atoms or other SMILES symbols (equality or parenthesis) – up to 18 symbols. 
Search result set sizes also shown in logarithmic scale. 
 
 
Fig. 9. Midazolam Result Sets for Increasing Fragment Size – Graph showing fragment size 
increasing from 2 to 18 symbols. Search result set sizes are shown in logarithmic scale. Square 
(blue) dots are individual results. Continuous (black) straight line is a fitted interpolation. 
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5 Discussion 
5.1 Non-ambiguous Fragments  
Three outcomes deserve emphasis among the preliminary results: 
 
a) Low ambiguity – since molecular fragments are very uncommon 
combinations of symbols, not found in natural language, there is virtually no 
ambiguity of meaning; search results are specific; 
b) Random fragments – arbitrary slicing of linearized strings, producing random 
fragments, is surprisingly efficient.  There is no need to slice them in the 
boundary of semantic units. Any slicing will work. 
c) Manageable Result Sets – the graphs in Fig. 7 and Fig. 9 show the clear trend 
of reducing result set sizes with increasing fragment size. Thus one can 
guarantee that above a certain fragment size threshold one gets result sets of 
the order of hundreds items. 
 
5.2 Drug-Lead Ontologies  
Knowledge repositories of experience relevant to drug discovery are accepted 
wisdom. We prefer the specialized compact drug-lead ontologies for Web search, 
since conventional ontologies are too large and not enough specific, to be efficient.  
We have chosen a widely accepted path to new medical drugs – viz. a fragment 
based approach. The proposed drug-lead ontologies are the vehicle to introduce 
fragments into search. Linearized components are essential to express structure. The 
specific choice – to favor SMILES rather than InChi – is not essential and can be 
changed, if necessary. 
5.2 Future Work  
To demonstrate the efficiency of the taken approach, one needs to make extensive 
investigation of a variety of drug families. 
This work adopted a drug-lead ontology with a dual role of knowledge repository 
and source of search inputs. A research issue of interest is the number and average 
sizes of the practical drug-lead ontologies. 
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5.3 Main Contribution  
The main contribution of this work is the idea of random fragments of linearized 
structures for Web search of new medical drugs. 
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